XOM

148.39

-1.11%↓

CVX

183.61

+0.66%↑

SHEL.US

78.77

+0.72%↑

COPNY

111.38

+0.34%↑

SLB

50.37

-0.51%↓

XOM

148.39

-1.11%↓

CVX

183.61

+0.66%↑

SHEL.US

78.77

+0.72%↑

COPNY

111.38

+0.34%↑

SLB

50.37

-0.51%↓

XOM

148.39

-1.11%↓

CVX

183.61

+0.66%↑

SHEL.US

78.77

+0.72%↑

COPNY

111.38

+0.34%↑

SLB

50.37

-0.51%↓

XOM

148.39

-1.11%↓

CVX

183.61

+0.66%↑

SHEL.US

78.77

+0.72%↑

COPNY

111.38

+0.34%↑

SLB

50.37

-0.51%↓

XOM

148.39

-1.11%↓

CVX

183.61

+0.66%↑

SHEL.US

78.77

+0.72%↑

COPNY

111.38

+0.34%↑

SLB

50.37

-0.51%↓

Search

Core Laboratories NV

Gesloten

18.57 2.31

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.48

Max

18.72

Belangrijke statistieken

By Trading Economics

Aanbevelingen

By TipRanks

Aanbevelingen

Sell

12 Maanden Prognose

-38.04% downside

Dividenden

By Dow Jones

Volgende Winsten

22 apr 2026

Volgende dividenddatum

9 mrt 2026

Volgende Ex Dividend datum

16 feb 2026

Core Laboratories NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 feb 2026, 23:21 UTC

Acquisities, Fusies, Overnames

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 feb 2026, 23:45 UTC

Marktinformatie

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 feb 2026, 23:40 UTC

Marktinformatie

Gold Falls on Possible Position Adjustments -- Market Talk

15 feb 2026, 23:06 UTC

Winsten

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 feb 2026, 23:04 UTC

Winsten

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 feb 2026, 23:04 UTC

Winsten

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Winsten

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Winsten

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 feb 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 feb 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 feb 2026, 22:52 UTC

Acquisities, Fusies, Overnames

Qube Shareholders to Receive A$5.20/Share in Cash

15 feb 2026, 22:52 UTC

Acquisities, Fusies, Overnames

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 feb 2026, 22:22 UTC

Acquisities, Fusies, Overnames

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 feb 2026, 22:17 UTC

Acquisities, Fusies, Overnames

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 feb 2026, 22:16 UTC

Acquisities, Fusies, Overnames

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 feb 2026, 22:14 UTC

Acquisities, Fusies, Overnames

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 feb 2026, 22:14 UTC

Acquisities, Fusies, Overnames

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 feb 2026, 20:48 UTC

Winsten

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 feb 2026, 20:47 UTC

Winsten

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 feb 2026, 20:46 UTC

Winsten

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 feb 2026, 20:45 UTC

Winsten

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 feb 2026, 20:44 UTC

Winsten

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 feb 2026, 20:44 UTC

Winsten

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 feb 2026, 20:43 UTC

Winsten

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 feb 2026, 20:42 UTC

Winsten

BlueScope Net Debt A$2.2 Million at Dec. 31

15 feb 2026, 20:42 UTC

Winsten

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 feb 2026, 20:41 UTC

Winsten

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 feb 2026, 20:40 UTC

Winsten

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 feb 2026, 20:40 UTC

Winsten

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 feb 2026, 20:39 UTC

Winsten

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Peer Vergelijking

Prijswijziging

Core Laboratories NV Prognose

Koersdoel

By TipRanks

-38.04% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 11.5 USD  -38.04%

Hoogste 11.5 USD

Laagste 11.5 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Core Laboratories NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Sell

1 ratings

0

Buy

0

Hold

1

Sell

Financieel

$

help-icon Live chat